Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06673134
Active, not recruiting Observational

Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease

NCT06673134 · tracked via the Priya Life Science China tracker
Sponsor
Tongji Hospital
Phase
Observational
Started
2023-12-01
Last updated
2025-09-04

Condition(s) studied

Crohn Disease

Investigational drug(s) / intervention(s)

enteral nutritionImmunotherapybiological agentsGlucocorticoidsfecal microbiota transplantation

enteral nutrition: exclusive enteral nutrition therapy or Partial enteral nutrition

Immunotherapy: Immunosuppressants therapy, Including thalidomide, azathioprine, methotrexate, etc

biological agents: Inflixima , domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd) and Adalimumab , etc

Glucocorticoids: Glucocorticoids treatments are given

fecal microbiota transplantation: Fecal bacteria transplantation treatment, transplantation routes include enema, TET route, capsule fecal bacteria route, etc

Study summary

To evaluate the clinical manifestations, treatment options, and improved clinical outcomeof children with Crohn's disease in real-world Settings: (1) analysis of clinical manifestations; (2) probability of using the same treatment options; (3) Clinical outcome;

Eligibility

Sex
ALL
Min age
1 Month
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria: * Children under 17 years old; * Children with a definite diagnosis of Crohn's disease; * Patients and their guardians must sign informed consent; Exclusion Criteria: * Other conditions deemed inappropriate by the doctor to participate in the study;

Primary outcome measure(s)

  • To evaluate the clinical manifestations, treatment options, and clinical outcomes of Crohn's disease in children in real-world Settings — 14 weeks
    14 weeks clinical response rate.

Trial sites (1)

FacilityCityRegionStatus
Tongji Hospital, Wuhan, 430030 Wuhan China

More Tongji Hospital trials in China

Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC Recruiting
CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants Recruiting
Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage Recruiting
Neoadjuvant PD-1 Inhibitor Plus SOX Chemotherapy With or Without Short-Course Radiotherapy for Locally Advanced Upper Gastric or GEJ Adenocarcinoma Starting soon
Dose-Effect Response in Acupuncture for Functional Constipation Recruiting

Other trials for the same condition

Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease Starting soon
Comparing Endoscopic Strictureplasty vs. Balloon Dilation in Crohn's Disease Strictures Recruiting
Effect of Acupuncture on Mild to Moderate Active Crohn's Disease Recruiting
Fecal Microbiota Transplantation in Pediatric Crohn's Disease Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06673134 on ClinicalTrials.gov ↗ ← All trials in China